BiotechTube

Humatrope

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Turner Syndrome

Conditions

Turner Syndrome

Trial Timeline

Dec 1, 2005 → Sep 1, 2015

NCT ID
NCT00266656

About Humatrope

Humatrope is a approved stage product being developed by Eli Lilly for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00266656. Target conditions include Turner Syndrome.

What happened to similar drugs?

2 of 7 similar drugs in Turner Syndrome were approved

Approved (2) Terminated (0) Active (5)
🔄SomatropinEli LillyPhase 3
🔄17 beta estradiolEli LillyPhase 3
🔄Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
✅r-hGHMerckApproved
🔄Somapacitan + Norditropin®Novo NordiskPhase 3
✅estradiolNovo NordiskApproved
🔄Somatropin (rDNA origin)IpsenPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00266656ApprovedCompleted

Competing Products

10 competing products in Turner Syndrome

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
17 beta estradiolEli LillyPhase 3
40
Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
40
r-hGHMerckApproved
43
Somapacitan + Norditropin®Novo NordiskPhase 3
44
estradiolNovo NordiskApproved
43
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patchNovo NordiskPhase 1
21
somatotropinPfizerPre-clinical
26
Lonapegsomatropin + SomatropinAscendis PharmaPhase 2
36
Somatropin (rDNA origin)IpsenPhase 3
37